Bone Biologics Corporation
Symbol: BBLG
NASDAQ
1.8001
USDDzisiejsza cena rynkowa
-0.1011
Wskaźnik P/E
0.0004
Wskaźnik PEG
1.58M
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Bone Biologics Corporation (BBLG) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0 | ||||||||||||||||
balance-sheet.row.inventory | 0 | -0.3 | -0.6 | 0 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.7 | 1 | 0 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.4 | 0 | 0.1 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | -0.8 | 0 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 0.5 | 2.5 | 0 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 0.8 | 2.5 | 0.1 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -80.9 | -72 | -70.5 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 83.8 | 77.9 | 77 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3.7 | 8.5 | 6.7 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 2.9 | 5.9 | 6.6 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -3 | -7.5 | -6.7 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0.2 | 0.3 | 0.2 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.1 | -0.2 | -0.3 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.8 | -0.4 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.1 | -1 | 0 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -0.9 | -2.2 | 0.5 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 5 | 4.4 | 6.9 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 1.1 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 5 | 4.4 | 7.9 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -4.5 | 0.9 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 3 | 7.5 | 6.7 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 7.5 | 6.7 | 0 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -9.6 | -3.6 | -1.2 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -9.6 | -3.6 | -1.2 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 9.4 | 3.7 | 1.1 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0.5 | 2.2 | -0.5 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -2.2 | 0.8 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 9.4 | -0.7 | 0 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | -9.4 | -3.7 | -1.1 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -8.9 | -1.5 | -1.6 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | -2.2 | 0 | ||||||||||||||||
income-statement-row.row.net-income | 0 | -8.9 | 0.7 | -1.6 |
Często zadawane pytania
Ile wynosi Bone Biologics Corporation (BBLG) aktywów ogółem?
Bone Biologics Corporation (BBLG) całkowite aktywa to 3737763.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to N/A.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.000.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -17.887.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.000.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.000.
Co to jest Bone Biologics Corporation (BBLG) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -8948731.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 0.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 9428303.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 0.000.